Kim et al. [17] showed by univariate analysis in their study of 159 patients with luminal (ER+ and/or PR+) breast carcinoma, that Bcl-2 positivity (at 33% cutoff for positivity) was one of the 4 prognostic factors associated with progression-free survival, the others being patient age at diagnosis (at a threshold of 35-years), tumor size (at a threshold of 2-cm), and nodal stage (positive / negative). This evidence concerns the gene BCL2 and breast carcinoma.